Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Patients With Locally Advanced Or Metastatic ER-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After CDK4/6 Inhibitor Therapy

Next Previous
Trial Profile

A Phase Ia/Ib Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Patients With Locally Advanced Or Metastatic ER-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After CDK4/6 Inhibitor Therapy

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GDC 0587 (Primary) ; Giredestrant (Primary) ; Omeprazole (Primary)
  • Indications Early breast cancer; HER2 negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Genentech

Most Recent Events

  • 05 Feb 2026 Planned End Date changed from 1 Jul 2029 to 1 Apr 2030.
  • 05 Feb 2026 Planned primary completion date changed from 1 Jul 2029 to 1 Apr 2030.
  • 12 Jan 2026 Planned initiation date changed from 15 Dec 2025 to 12 Jan 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top